Ligand Pharma (LGND) Tops Q4 EPS by 1c, Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $21.2 million versus the consensus estimate of $24.97 million.

GUIDANCE:

Ligand Pharma sees FY2016 EPS of $3.37-$3.42, versus the consensus of $3.34. Ligand Pharma sees FY2016 revenue of $114-118 million, versus the consensus of $114 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• JPMorgan Downgrades Societe Generale SA (GLE:FP) (SCGLY) to Neutral
• TD Cowen Reiterates Hold Rating on Leidos Holdings (LDOS)